Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial - Nature Medicine

South Africa News News

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial - Nature Medicine
South Africa Latest News,South Africa Headlines
  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 53%

In a phase 2 study, enoblituzumab - a humanized Fc-engineered B7-H3–targeting antibody - was safe and showed preliminary evidence of potential clinical activity in men with high-risk ProstateCancer DocEShenderov HopkinsMedicine

) Total unique T-cell clonotypes expanded in tumor or peripheral blood at prostatectomy versus fraction of peripheral clones expanded and detected intratumorally. Each point on the scatter plots represents a patient. Blue dots indicate responders for a given outcome and red dots indicate non-responders.

Genes that remained significant after Benjamini and Yekutieli False Discovery Rate are in blue and labeled. Matched 1:1 untreated controls by grade group, stage, margins, block age [within 2 years], age [within 2 years], and self-reported race. Tumor regions isolated by macrodissection. Extended Data Fig. 6 Grouped boxplots of difference in mean log2 marker level of upregulated proteins by clinical outcome using DSP of the TME in pretreatment biopsies and post-treatment prostatectomies following B7-H3 monoclonal antibody treatment., protein marker status by PSA response at 12 months after prostatectomy versus PSA recurrence. Protein expression was assessed in n = 27 tissue samples from n = 32 patients .

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NatureMedicine /  🏆 451. in US

South Africa Latest News, South Africa Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Use of mobile diagnostics and digital clinical trials in cardiology - Nature MedicineUse of mobile diagnostics and digital clinical trials in cardiology - Nature MedicineUse of mobile diagnostics and digital clinical trials in cardiology. Comment from Sinje Gehr, Nandha Kumar Balasubramaniam & Christoph Russmann, Health Campus Goettingen, harvardmed. Published as part of our series - Rethinking Evidence in Medicine.
Read more »

'You forget to eat': How Ozempic went from diabetes medicine to blockbuster diet drug'You forget to eat': How Ozempic went from diabetes medicine to blockbuster diet drugThe antidiabetic drug Ozempic has been called 'the worst-kept secret in Hollywood.' It causes rapid weight loss — and celebs have scrambled to get their hands on it for off-label, aesthetic purposes. But its popularity has a price.
Read more »

AI chatbots like ChatGPT could soon play a significant role in medicineAI chatbots like ChatGPT could soon play a significant role in medicineAdvanced LLM chatbots such as ChatGPT have been found to provide surprisingly accurate medical information.
Read more »

'You forget to eat': How Ozempic went from diabetes medicine to blockbuster diet drug'You forget to eat': How Ozempic went from diabetes medicine to blockbuster diet drugThe Novo Nordisk diabetes medication was found to cause significant weight loss in users and has since become a blockbuster drug and very big business.
Read more »

Disputed Variant of Ice Could Exist in Nature After All, According to a New ExperimentDisputed Variant of Ice Could Exist in Nature After All, According to a New ExperimentRight down on a molecular level, water ice can form out of a rich variety of structures.
Read more »

An atlas of genetic scores to predict multi-omic traits - NatureAn atlas of genetic scores to predict multi-omic traits - NatureA machine learning approach is used to analyse multi-omics (proteomics, metabolomics and transcriptomics) data, producing genetic scores for more than 17,000 biomolecular traits in human blood, and identifying possible associations with disease.
Read more »



Render Time: 2025-02-28 19:08:52